4.29
-0.09(-2.05%)
Currency In USD
| Previous Close | 4.38 |
| Open | 4.32 |
| Day High | 4.38 |
| Day Low | 4.21 |
| 52-Week High | 15.47 |
| 52-Week Low | 3.76 |
| Volume | 1.12M |
| Average Volume | 993,616 |
| Market Cap | 399.89M |
| PE | -0.98 |
| EPS | -4.36 |
| Moving Average 50 Days | 6.18 |
| Moving Average 200 Days | 6.12 |
| Change | -0.09 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $122.57 as of February 21, 2026 at a share price of $4.29. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $143.33 as of February 21, 2026 at a share price of $4.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
GlobeNewswire Inc.
Feb 19, 2026 2:15 PM GMT
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical ChemistrySALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, anno
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
GlobeNewswire Inc.
Feb 16, 2026 9:15 PM GMT
Management will participate in three upcoming investor healthcare conferencesSALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
GlobeNewswire Inc.
Jan 27, 2026 1:50 PM GMT
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, t